82891
document
Angiotensin converting enzyme inhibition does not affect the response to exogenous angiotensin II in the human forearm . Suppression of endogenous levels of angiotensin II by angiotensin converting enzyme inhibition , may result in up-regulation of vascular AT1 receptors . We have evaluated the effects of orally administered enalapril on angiotensin II induced vasoconstriction in the human forearm . Subjects received in random order , enalapril ( 20 mg ) or matched placebo daily for 2 weeks . Forearm blood flow response to increasing doses of angiotensin II was measured using venous occlusion plethysmography at the beginning of the study and at the end of each 2 week treatment period . Treatment with enalapril significantly reduced plasma angiotensin II levels and supine blood pressure compared with placebo . The percentage reductions in forearm blood flow in the infused arm , in response to the maximum dose of angiotensin II ( 50,000 fmol min-1 ) were 48.1 +/- 3.6 % at baseline , 57.5 +/- 3.6 % on placebo and 54.5 +/- 4.2 % on enalapril . The differences were not significantly different . This demonstrates that suppression of plasma angiotensin II for a 14 day period does not enhance the response to exogenous intra-arterial angiotensin II in the human forearm of healthy salt replete subjects .
82892
Intervention_Pharmacological
enalapril
82893
Intervention_Pharmacological
enalapril
82894
Intervention_Control
placebo
82895
Outcome_Physical
Forearm blood flow
82896
Outcome_Physical
plasma angiotensin II levels
82897
Outcome_Physical
supine blood pressure
82898
Outcome_Physical
reductions in forearm blood flow
82899
Participant_Condition
healthy salt replete